Background Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the eff ect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy.
Introduction
Tuberculosis is the main cause of morbidity and mortality in people infected with HIV-1. The burden is greatest in sub-Saharan Africa, especially in southern Africa where more than 50% of new tuberculosis cases are co-infected with HIV-1. 1 Findings of a meta-analysis 2 of randomised controlled trials showed that isoniazid preventive therapy decreased the risk of tuberculosis by 32% in people with HIV-1 who were not on combination antiretroviral therapy. Strong statistical evidence for benefi t was only reported in individuals who had positive tuberculin skin tests. However, there was heterogeneity of isoniazid preventive therapy duration and follow-up between the included studies. Antiretroviral therapy independently reduces the risk of tuberculosis by 65%, 3 but tuberculosis is more common in people infected with HIV than in people without HIV. 4 Data from three retrospective observational cohort studies [5] [6] [7] suggested a greater eff ect of combined antiretroviral therapy and isoniazid preventive therapy on the risk of tuberculosis than antiretroviral therapy alone. The proportion of individuals who received both treatments concurrently was unclear in the Brazilian study, 6 and isoniazid preventive therapy preceded antiretroviral therapy in the South African study. 7 In the BOTUSA randomised controlled trial 8 done in Botswana, isoniazid preventive therapy for 36 months was more benefi cial than treatment for 6 months in individuals who started antiretroviral therapy. However, antiretroviral therapy was prescribed in some of the participants at diff erent times during follow-up when participants fulfi lled criteria for antiretroviral therapy initiation. Thus, the independent eff ect of isoniazid preventive therapy in patients on antiretroviral therapy could not be established. In an Indian study, 9 in which the eff ect of 6 months of ethambutol and isoniazid was compared with 36 months of isoniazid in patients with HIV, some participants started antiretroviral therapy, but the eff ect of concomitant antiretroviral therapy and isoniazid preventive therapy on effi cacy and toxic eff ects was not reported.
Concurrent isoniazid preventive therapy and antiretroviral therapy could result in shared toxic eff ects, notably hepatitis and neuropathy. Furthermore, isoniazid inhibits several cytochrome P450 isoenzymes, 10 which metabolise many antiretroviral drugs. This inhibition can cause increased antiretroviral concentrations, which might exceed the toxic threshold. Therefore, whether isoniazid preventive therapy further reduces the risk of tuberculosis in people on antiretroviral therapy is important to establish, and any additional toxic eff ects should be quantifi ed.
We aimed to assess the eff ect of isoniazid preventive therapy on the risk of active tuberculosis in people with HIV-1 concurrently receiving antiretroviral therapy. Our secondary objectives were to establish toxic eff ects of treatment and all-cause mortality.
Methods

Study design and participants
We did a pragmatic individually randomised doubleblind, placebo-controlled trial between Jan 31, 2008, and Sept 31, 2011, of isoniazid preventive therapy in people with HIV-1 on antiretroviral therapy at the Ubuntu clinic in Khayelitsha, Cape Town, South Africa.
Adults (≥18 years) were recruited among antiretroviral therapy clinic attendees consecutively listed in study screening logs. All participants had baseline tuberculosis symptom screening and sputum mycobacterial culture.
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Exclusion criteria were active tuberculosis or suspicion of active tuberculosis as established by symptom screening, present or previous treatment of latent tuberculosis infection; present treatment with fl uoroquinolones or other antibiotics with marked antituberculous activity, history of intolerance to isoniazid; grade 3 or 4 baseline alanine transaminase, grade 3 or 4 peripheral neuropathy, pregnancy, or less than 6 weeks post partum. We used tables from the AIDS Clinical Trials Group 12 to grade toxic eff ects of treatment for people on antiretroviral therapy.
Ethics approval was obtained from the ethics review boards of the University of Cape Town, Médecins Sans Frontières, and the London School of Hygiene & Tropical Medicine. Written consent or a thumb-print was needed from all participants before screening. Four people on a data safety and monitoring board provided oversight during the study.
Randomisation and masking
Patients were randomly assigned (1:1) to receive daily self-administered isoniazid or matching placebo dosed according to bodyweight (200 mg per day for <50 kg or 300 mg per day for ≥50 kg) together with 25 mg of pyridoxine for 12 months (could be completed during 15 months). Randomisation was by random number generator software (in Excel) and was stratifi ed by antiretroviral therapy status at baseline: just started antiretroviral therapy (start-antiretroviral therapy) versus established on antiretroviral therapy (on-antiretroviral therapy). Partici pants, clinicians, and local pharmacy staff were masked to treatment allocations. The appendix gives further details on randomisation and masking.
Procedures
At each visit participants were asked about symptoms of adverse drug events: nausea, vomiting, or right upperquadrant pain, rashes, and new or worsening peripheral neuropathy. During the intervention phase, we measured alanine trans aminase concentration at baseline, every month for the fi rst 3 months, and every 3 months thereafter. Protocol-specifi ed reasons for permanent cessation of study drug because toxic eff ects were new or worsening peripheral neuropathy of grade 2 or more, grade 3 or 4 raised alanine transaminase concentrations, or clinical hepatitis, new rash grade 2 or more. CD4 lymphocyte counts and viral loads were measured according to clinic protocols (initially every 6 months then every year after the fi rst year on antiretroviral therapy from 2010). Clinic nurses and doctors followed up participants routinely according to regular clinic schedules; schedules were aligned with antiretroviral therapy appointments to aid participant retention. Pharmacy staff dispensed the study drug along with other routine prescriptions. Pharmacy refi ll records were used to monitor adherence to antiretroviral therapy and the study drug.
A standard tuberculosis symptom screen was done at each clinic visit. Two sputum specimens were obtained from suspected cases of tuberculosis for microscopy by auramine staining and for mycobacterial culture. Species identifi cation and drug sensitivity testing for isoniazid and rifampicin was done for all positive isolates (BACTEC mycobacterial growth indicator tube, Becton Dickinson Microbiology Systems, Cockeysville, MD, USA). Specimens were processed at the National Health Laboratory Service, Cape Town, South Africa. Sputum induction was done on individuals unable to expectorate spontaneously. Needle aspiration biopsy was done in patients who presented with suspected tuberculosis lymphadenitis. Patients suspected to have extrapulmonary tuberculosis and needing further investigation were referred to an HIV specialist clinic (G F Jooste Hospital, Cape Town, South Africa). Urine for acid fast bacilli smear and culture was requested from all participants with suspected extrapulmonary tuberculosis. Infectious disease specialists (GM and RJW) were consulted for diffi cult cases. Tuberculosis treatment was started for all patients who met the case defi nition for tuberculosis ( A tuberculin skin test (2TU RT23 PPD, Statens Serum Institut, Denmark) and interferon gamma release assay (QuantiFERON gold in-tube, Cellestis, Australia) were done as part of a nested study. 13 These tests were done at the baseline screening visit, before application of specifi c inclusion and exclusion criteria, and in participants who suggested willingness to return for tuberculin skin test results. Manufacturer's criteria for interferon gamma release assay positivity were used (≥0·35 IU/mL); tuberculin skin test induration of 5 mm or more was deemed positive.
Outcomes
The primary endpoint was time to development of incident tuberculosis (defi nite, probable, or possible) during the study. Secondary endpoints were time to death or the risk of adverse drug reaction. For the primary outcome we calculated person-time at risk from date of randomisation to earliest of tuberculosis (the clinic visit date tuberculosis was diagnosed and registered in the clinic database or notifi ed in the tuberculosis register); death (death ascertainment was by report to the clinic staff and augmented from the national death register); loss to follow-up (participants were defi ned as lost to follow-up if their last clinic contact was more than 6 months before the date of closure of the study database, which was censored at their last contact date); transferred out (excluding participants transferred out for care at another clinic in the district since outcome data is available on the province-wide patient electronic register and from the national tuberculosis register); or study closure.
Statistical analysis
Results of this trial were reported in accordance with the CONSORT guidelines for reporting pragmatic trials. 14 We did a modifi ed intention-to-treat analysis; we excluded any participants who withdrew from the study before receiving the study drug or those whose baseline sputum culture results suggested prevalent tuberculosis after randomisation. We used the log-rank test to compare survival curves by treatment group. The hazard ratio (HR) for the treatment eff ect and the associated 95% CIs were calculated by Cox proportional hazards regression. To assess the durability of the treatment eff ect, follow-up time was split into three time groups (0-11 months, 12-23 months, and ≥24 months) and we used the likelihood ratio test to test for eff ect modifi cation by time interval. At the time of the analysis, we specifi ed the eff ects of isoniazid by time since randomisation and by tuberculosis infection status at enrolment. Time from randomisation to death was compared by study group and HRs were calculated from the Cox proportional hazards model.
A fi nal sample size of 1368 had 80% power to detect a 35% reduction in the incidence of tuberculosis in the intervention versus control group assuming a rate of 8·5 per 100 person-years in the control group, a type I error of 0·05 and a 30% loss to follow-up in each group (appendix). 15, 16 All analyses were done with STATA (version 12.0).
This study is registered with ClinicalTrials.gov, number NCT00463086. 
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Screening started on Nov, 1, 2007, the fi rst participant was randomised on Jan 31, 2008, and the last completed the study drug on Oct 31, 2010, and study closure was on Sept 31, 2011. Of 2138 individuals with HIV assessed for eligibility, 1369 participants were enrolled in the study and randomly assigned to receive either placebo or isoniazid (fi gure 1). The appendix shows characteristics at screening of the 478 participants who were screened but not randomly assigned, and the 1369 (64%) who were. The proportion of participants already established on antiretroviral therapy was lower in individuals not randomly assigned and the proportion with previous tuberculosis was higher in those randomly assigned (42·2% vs 34·5%). 39 culture-positive prevalent tuberculosis cases were diagnosed after randomisation, and one person did not receive the study drug, leaving 1329 in the modifi ed intention-to-treat analysis; 667 received placebo and 662 received isoniazid. Baseline characteristics at enrolment for those in the modifi ed intention-to-treat analysis were similarly distributed between the study groups ( in the start-antiretroviral therapy group. The appendix provides reasons for why placebo or isoniazid was stopped during the active intervention phase by study group. The maximum follow-up was 3·7 years, with a median of 2·5 years (IQR 2·1-3·1). Numbers of patients at study closure who transferred out or were lost to follow-up were similar between study groups. The proportion lost to follow-up in each group was 11%; far less than the 30% initially assumed (fi gure 1). For participants in each group who completed 12 months of the study drug (n=1100), a median of 360 doses (IQR 330-390) were dispensed during a median of 12 months on the study drug (IQR 11-13 months; appendix). We recorded no diff erence in median months on study drug and total doses dispensed between study groups.
95 cases of tuberculosis developed during 3226·5 personyears of follow-up (58 on placebo and 37 on isoniazid; 34/95 [36%] were culture-confi rmed; table 2). 56 of 95 (59%) cases were diagnosed at the study site, 37 of 95 (39%) at satellite clinics, and 7 of 95 (7%) were identifi ed through linkage to national health laboratory service and provincial electronic tuberculosis notifi cations data. 72 of 95 (76%) cases developed during the fi rst 2 years of follow-up after randomisation (fi gures 2-4). The overall rate of tuberculosis was 2·9 per 100 person-years; higher in the placebo group than the isoniazid group (table 2) . Adjustment for time-updated CD4 count did not signifi cantly change the overall HR for tuberculosis (HR 0·64, 95% CI 0·42-0·96). Eight of the 95 participants with tuberculosis subsequently died during treatment (two on isoniazid and six on placebo). We did drug sensitivity testing on 25 of the 34 culture-confi rmed cases of tuberculosis: four had multidrug-resistant tuberculosis (three on placebo and one on isoniazid), and two had isoniazid mono-resistance (both on isoniazid).
The eff ect of isoniazid on the risk of tuberculosis was greatest in the fi rst year of follow-up when individuals were still on treatment (unadjusted HR 0·52, 95% CI 0·27-1·01; fi gure 4). The eff ect decreased over time (at 12-23 months, HR 0·61, 0·30-1·21, and at 24 months, HR=0·78, 95% CI 0·39-2·0). However, Data are median (IQR) or n (%). ART=antiretroviral therapy. TST=tuberculin skin test. IGRA=interferon gamma release assay. Start-ART=just started ART. On-ART=established on ART. D4T=stavudine. AZT=azidothymidine or zidovudine. 3TC=lamivudine. EFV=efavirenz. NVP=nevirapine. *n=602 for placebo, 585 for isoniazid, and 1187 in total. †n=657 for placebo, 652 for isoniazid, and 1309 in total. ‡Other ART regimens: AZT/didanosine/lopinavir/ritonavir (two on placebo), 3TC/EFV/tenofovir (nine on placebo and 12 on isoniazid), D4T/3TC/lopinavir/ritonavir (one on placebo and one on isoniazid), AZT/3TC/lopinavir/ritonavir (two on placebo), 3TC/NVP/tenofovir (three on placebo and one on isoniazid), 3TC/tenofovir/lopinavir/ritonavir (one on placebo). Table 1 : Baseline characteristics at enrolment of individuals included in modifi ed intention-to-treat analysis, by study group statistical power was insuffi cient to show formal interaction by time since randomisation (p=0·34, assuming linear eff ect). The appendix shows tuberculosis rates per study period since randomisation. Table 3 shows analyses to assess the eff ect of antiretroviral therapy with isoniazid on time to tuberculosis stratifi ed by tuberculin skin test or interferon gamma release assay status. The eff ect of isoniazid on tuberculosis incidence was greater in participants with negative tuberculin skin tests or interferon gamma release assay than in those tested positive, but we noted weak statistical evidence that the eff ects were diff erent (interaction p=0·58 for tuberculin skin test and p=0·24 for interferon gamma release assay) after adjustment for baseline CD4 count and antiretroviral therapy status on enrolment. Participants who did not accept tuberculin skin test or interferon gamma release assay testing did not diff er from those who did with respect to age, sex, CD4 count, previous history of tuberculosis, or antiretroviral therapy status (appendix).
We recorded 37 deaths from all causes during 3579 person-years of follow-up (21 on placebo and 16 on isoniazid; table 2). The overall rate of all-cause mortality was one per 100 person-years; rates were slightly lower in the isoniazid (0·9 per 100 person-years) compared with the placebo group (1·2 per 100 person-years; HR 0·72, 95% CI 0·34-1·34, log-rank p=0·32; fi gure 2). Further details on the 37 deaths were obtained from hospital records or family reports; eight were tuberculosis deaths (two isoniazid and six placebo), 13 were due to non-tuberculosis reasons deemed unrelated to the study drug (six isoniazid and seven placebo; eight happened during the intervention phase), and the rest of the reasons were unknown (eight isoniazid and eight placebo; two happened during the intervention phase). The appendix provides a summary of specifi c causes of death by study group.
We recorded no diff erence between study groups in study drug discontinuation due to any adverse event ( 
Figure 2: Time to tuberculosis from randomisation
The placebo group was given antiretroviral therapy plus placebo and the isoniazid group was given antiretroviral therapy plus isoniazid. Numbers show the number of participants followed up at each timepoint, and the numbers in parentheses show new tuberculosis cases in each period. Log-rank test p value for equality of survival curves=0·02. 
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(2) concentration, clinical hepatitis, new or worsening grade 2, or more rash or peripheral neuropathy; RR 1·5, 95% CI 0·84-2·7; table 4). 34 participants had grade 3 or more raised alanine transaminase concentration, which resulted in termination of the study drug in 29 participants (in two participants grade 3 alanine transaminase was reported only in month 12 and results were obtained after the study drug was completed, subsequent alanine transaminase in three participants were all <grade 3).
The risk of stopping the study drug because of grade 3 or above raised alanine transaminase alone was 2·9% on isoniazid compared with 1·5% on placebo (RR 1·9, 0·90-4·09). The risk of stopping the drug was 2·8% if on isoniazid and 1·6% on placebo (RR 1·7, 0·72-4·12) for the on-antiretroviral therapy group, and 3·0 % and 1·1% for the start-antiretroviral therapy group (RR 2·7, 0·54-12·98; data not shown).
The appendix shows estimates of the numbers needed to treat or harm. 25 individuals on antiretroviral therapy need to be treated with isoniazid to prevent a case of tuberculosis. 100 individuals on antiretroviral therapy need to be treated with isoniazid to result in harm as defi ned by participants stopping the study drug because of presumed toxic eff ects.
Discussion
12 months of isoniazid preventive therapy independently reduced the incidence of tuberculosis in participants concurrently on antiretroviral therapy by 37% (panel). The risk-to-benefi t ratio was favourable with the number needed to harm four times higher than the number needed to treat to benefi t with isoniazid preventive therapy. The greatest benefi t from isoniazid preventive therapy seemed to be in the fi rst year; however, evidence was weak for the decreased eff ect with time. Isoniazid preventive therapy benefi t was greater in individuals who had negative tuberculin skin tests and interferon gamma release assays than those who tested positive, although statistical evidence for interaction was weak. Implementation of Table 3 : Eff ect of isoniazid on the rate of all tuberculosis stratifi ed by markers of Mycobacterium tuberculosis infection status at enrolment
Figure 4: Time to death from randomisation
The placebo group was given antiretroviral therapy plus placebo, and the isoniazid group was given antiretroviral therapy plus isoniazid. Log-rank test p value for equality of survival curves=0·32. Placebo  Isoniazid   0  1  2  3  4 667 662
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(1) isoniazid preventive therapy in an antiretroviral therapy clinic will probably be easier than in pre-antiretroviral therapy care because individuals on antiretroviral therapy receive regular drugs and have more frequent follow-up visits. A strength of our study was the use of sputum cultures to exclude tuberculosis at baseline. Some of the eff ect of isoniazid preventive therapy reported in studies that did not rigorously exclude tuberculosis might have arisen as a result of the eff ect of isoniazid monotherapy on subclinical disease. 20 The benefi t of isoniazid preventive therapy in individuals on antiretroviral therapy seemed to decrease gradually over time rather than rebound rapidly soon after cessation. However, our study was underpowered to assess duration of benefi t beyond the study period. The risk of active tuberculosis decreases over time because of improvements in CD4 counts mediated by antiretroviral therapy, 3 which might have masked loss of eff ect of isoniazid preventive therapy after completion. Findings of studies of isoniazid preventive therapy in preantiretroviral therapy cohorts have shown that 6 months of isoniazid preventive therapy has a short-term benefi t. 21, 22 A similar, but more pronounced, loss of eff ect was seen in the 6 month isoniazid preventive therapy group of the BOTUSA study, 8 in which 45% of the participants started antiretroviral therapy according to need during the study period. 8 Longer courses (>6 months) of isoniazid preventive therapy for all individuals with HIV are now recommended by WHO. 23 Our fi ndings, together with those of the BOTUSA study, support the use of longerterm isoniazid preventive therapy in individuals on antiretroviral therapy living in moderate or high incidence areas. However, in routine clinical practice, the risk of non-adherence and treatment discontinuations might be higher in individuals prescribed extended isoniazid preventive therapy than in those prescribed shorter courses. 17 In our study participants on antiretroviral therapy with negative tuberculin skin test results benefi ted more from isoniazid preventive therapy than participants with positive tuberculin skin tests. We recorded similar trends in eff ect by interferon gamma release assay status. This fi nding was unexpected because results of a metaanalysis 2 of randomised controlled trials of isoniazid preventive therapy without antiretroviral therapy showed signifi cant benefi t only in those with a positive tuberculin skin test. It is not clear why tuberculin skin test positive individuals not on antiretroviral therapy might benefi t more from isoniazid preventive therapy than do individuals with tuberculin skin test negative results. Individuals who test negative might not benefi t as much because they are not latently infected with M tuberculosis. However, in areas with a high prevalence of tuberculosis, many of the negative tuberculin skin test results in individuals with HIV are likely to be false negatives, especially in those with low CD4 counts. 24 Isoniazid preventive therapy might be eff ective in antiretroviral therapy-naive patients with a positive tuberculin skin test because eff ective isoniazid preventive therapy needs some acquired immunity to M tuberculosis, for which tuberculin skin test is a crude measure. Isoniazid modifi es the immune response to tuberculosis, potentially by releasing mycobacterial antigens. 25 In individuals who have positive tuberculin skin tests, antiretroviral therapy is likely to augment pre-existing
Panel: Research in context
Systematic review
We searched PubMed for systematic reviews, meta-analyses, and randomised controlled trials of the effi cacy of tuberculosis preventive therapy on incident tuberculosis in adults with HIV on combination antiretroviral therapy published between Jan 1, 1996, and Jan 1, 2014. We included the following search terms: "antiretroviral therapy" OR "HIV" AND "tuberculosis" AND "isoniazid" OR "preventive therapy". We identifi ed one recent meta-analysis, 2 and four subsequent trials that were not included in the meta-analysis, 8, 9, 17, 18 one was a cluster randomised trial of a complex intervention. 18 We did not identify any randomised controlled trials of tuberculosis preventive therapy in adults on concurrent antiretroviral therapy.
Interpretation
Findings of the meta-analysis showed that preventive therapy reduced incident tuberculosis in adults with HIV with positive tuberculin skin tests, but not in those with negative tuberculin skin tests. 2 However, the placebo-controlled trials included in the meta-analysis were all from the pre-antiretroviral therapy era, or were done in areas before antiretroviral therapy access. Measurement of the effi cacy and safety of tuberculosis preventive therapy in people on antiretroviral therapy is important because antiretroviral therapy also reduces the risk of tuberculosis, toxic eff ects of preventive therapy might be enhanced, and because 25·9 million of the estimated 35·3 million living with HIV in 2012, qualifi ed for antiretroviral therapy according to 2013 WHO guidelines. 19 Three subsequent trials compared longer duration isoniazid preventive therapy with other preventive therapy regimens. 8, 9, 17 The three trials of longer duration isoniazid preventive therapy were done in antiretroviral therapynaive individuals (except for 2% of participants in the BOTUSA study 8 ), with participants starting antiretroviral therapy according to clinical need during follow-up. 36 months isoniazid preventive therapy was more eff ective than 6 months in the BOTUSA study, with the benefi t restricted to those who were tuberculin skin tests positive, 8 but no benefi t was recorded in the other two trials with smaller sample sizes. 9, 17 In the BOTUSA study, antiretroviral therapy for 1 year reduced tuberculosis incidence by 50%. A cluster randomised trial 18 found that improved tuberculosis screening and isoniazid preventive therapy reduced incident tuberculosis, which was independent of the eff ects of concomitant antiretroviral therapy at baseline. 12 months of isoniazid preventive therapy reduced the incidence of tuberculosis in individuals on antiretroviral therapy, was easy to implement in an antiretroviral therapy clinic, and was well tolerated. Unlike other studies, we found that participants on antiretroviral therapy with negative tuberculin skin test or interferon gamma release assay benefi ted more from isoniazid preventive therapy than test-positive participants. Until a more predictive test for latent tuberculosis infection or a multivariate algorithm that predicts benefi t in the context of antiretroviral therapy is available, isoniazid preventive therapy should be recommended to all patients receiving antiretroviral therapy in moderate or high incidence areas irrespective of tuberculin skin test status. Future studies should explore improved diagnostics for latent tuberculosis infection, large-scale implementation of longer duration of isoniazid preventive therapy, or more sterilising preventive therapy regimens, in people on antiretroviral therapy.
immunity to M tuberculosis, and the incremental benefi t of isoniazid preventive therapy might be small or nonexistent. By contrast, in individuals with negative tuberculin skin tests results, antiretroviral therapy improves acquired immunity to M tuberculosis in individuals who have been exposed to M tuberculosis, as shown by positive results on repeat skin test. Investigators of a recent Ugandan study 26 reported a high negative to positive tuberculin skin test conversion rate of 30·9 per 100 person-years during the fi rst 6 months after antiretroviral therapy initiation. Isoniazid preventive therapy might be eff ective in this setting of early restoration of acquired immunity. In patients on antiretroviral therapy, the effi cacy of isoniazid preventive therapy might not be strongly linked to tuberculin skin test or interferon gamma release assay status.
More participants in the isoniazid group than the placebo group stopped taking the study drug because of adverse events, with a relative risk similar to that reported in the Cochrane meta-analysis 2 of isoniazid preventive therapy trials in patients not yet started on antiretroviral therapy (RR 1·5, 95% CI 0·84-2·7 vs 1·66, 1·09-2·51). Additionally, we did not fi nd strong evidence for increased risk of cessation of study drug because of toxic eff ects in individuals newly starting antiretroviral therapy. These data suggest no additive toxic eff ects of isoniazid preventive therapy in patients concurrently receiving antiretroviral therapy.
Our study had some limitations. First, the study did not have suffi cient statistical power to show clear diff erences in eff ect estimates by tuberculin skin test or interferon gamma release assay status, or to establish the duration of benefi t of isoniazid preventive therapy in individuals on antiretroviral therapy, for which a larger sample size or longer duration of follow up would have been needed. Second, although we aimed to confi rm as many cases of incident tuberculosis as possible with culture at the study clinic, 39% of cases were diagnosed at satellite clinics where diagnostic confi rmation might not have been as rigorous. Thus, the incidence of culture-confi rmed tuberculosis might have been underestimated. Third, we did not repeat tuberculin skin tests and interferon gamma release assays early in the study. The prospective usefulness of one test result obtained at screening might be reduced with increasing study follow-up and time on antiretroviral therapy. Repeat testing after several months of antiretroviral therapy might have allowed more accurate measurement of the presence of latent tuberculosis infection. [26] [27] [28] [29] [30] [31] Fourth, the rate of tuberculosis in the placebo group was lower than the rate assumed, which we had estimated from two local cohort studies 32, 33 available to us when the study started. Possible explanations for the lower than expected tuberculosis incidence are high case ascertainment by screening with sputum cultures, which decreases tuberculosis incidence after start of antiretroviral therapy, 34 and increased CD4 counts at antiretroviral therapy initiation, 35 which is the most important risk factor for incident tuberculosis after antiretroviral therapy initiation. 36 However, person-years were higher than we had assumed because loss to follow-up was lower than expected and duration of follow-up was longer than planned because of slow recruitment. Our study had 80% statistical power for the recorded eff ect size of 37% of isoniazid preventive therapy for the primary endpoint, suggesting that the longer period of observation compensated for the lower than expected tuberculosis incidence. Fifth, fi ndings of our study showed a more modest eff ect than previously shown in mostly observational studies. [5] [6] [7] Issues with methods in previous studies prevented an independent assessment of the eff ect of isoniazid preventive therapy with antiretroviral therapy. [5] [6] [7] [8] The small eff ects described, and the resultant high rate of tuberculosis in the intervention group, suggest antiretroviral therapy plus isoniazid preventive therapy alone might not be adequate to control tuberculosis at the population level. Sixth, our study results might not be generalisable to settings of low tuberculosis incidence where background rates of M tuberculosis exposure are low. Finally, we did a pragmatic trial in a busy antiretroviral therapy and tuberculosis integrated clinic; study procedures would probably have been more rigorous in a dedicated fully staff ed study clinic, but doing the study in a busy antiretroviral therapy clinic with minimum additional staffi ng allowed us to assess implementation of isoniazid preventive therapy.
In summary, 12 months of isoniazid preventive therapy reduced the incidence of tuberculosis in individuals infected with HIV-1 established on antiretroviral therapy or newly starting antiretroviral therapy and seemed well tolerated. In this high incidence setting, individuals on antiretroviral therapy who have negative tuberculin skin test or interferon gamma release assay might also benefi t from isoniazid preventive therapy. Implementation of isoniazid preventive therapy is feasible in busy antiretroviral therapy clinics in settings with high rates of HIV and tuberculosis comorbidity.
